Mice Model Market by Type, Technology, Therapeutic Area, Application

List of Tables

[187 Pages Report] The Mice Model Market size was estimated at USD 1.49 billion in 2023 and expected to reach USD 1.61 billion in 2024, at a CAGR 8.34% to reach USD 2.61 billion by 2030.

Mice models are laboratory mice (Mus musculus) used by scientists and researchers for biomedical research and studies related to genetic engineering, drug discovery, and therapeutic testing. These models are pivotal in mimicking human disease processes due to the genetic, biological, and behavioral similarities between humans and mice. Mice models enable the scientific community to understand disease mechanisms, assess drug efficacy, and explore potential treatments before they are tested in humans. The increasing demand for personalized medicine, the growing prevalence of various genetic disorders, and a surge in biomedical research involving cancer, cardiovascular diseases, and neurological disorders enhanced the usage of mice models. The rise in regulatory approvals for pharmaceutical drugs also necessitates extensive preclinical studies, further propelling the demand for mice models. Despite the significant growth, the mice model market faces several challenges, such as ethical concerns related to animal testing, the high cost of creating and maintaining genetically engineered mice models, and the complexity of reproducing human diseases in mice. However, the continual development of CRISPR/Cas9 gene-editing technology presents novel avenues for creating more accurate and diverse disease models. Additionally, the increasing investment in biomedical research and development by both public and private sectors worldwide offers a significant boost to the market.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.49 billion
Estimated Year [2024]	USD 1.61 billion
Forecast Year [2030]	USD 2.61 billion
CAGR (%)	8.34%

Type: Growing significance of genetically engineered mice for evaluating gene therapy outcomes

Conditioned or surgically modified mice are specifically altered through surgical interventions to create models that represent human conditions not naturally occurring in the mouse genome. These modifications can include the removal of specific organs, the introduction of tumors, or the creation of injury models. This methodology allows for the study of disease mechanisms, the development of surgical techniques, and the evaluation of therapeutics in a controlled environment, closely mimicking the human physiological conditions they aim to replicate. Genetically engineered mice (GEM) are created by manipulating their genetic material. Techniques such as gene knockout, gene knock-in, and transgenesis are employed to introduce, remove, or alter specific genes within the mouse genome. This category of mice models is important for studying gene function, the genetic basis of diseases, and the potential effects of genetic modifications. Hybrid/congenic mice are produced through controlled breeding strategies to combine genetic material from two or more strains to achieve specific genetic backgrounds. Hybrid mice result from mating two different inbred strains, offering heterozygosity and broader genetic diversity, which is beneficial for general health and reproductive performance. Congenic mice, on the other hand, are created by backcrossing hybrids to one of the original inbred strains for multiple generations, allowing for the isolation of specific genetic traits or loci. Inbred mice are derived from at least 20 generations of brother-sister or parent-offspring mating, which results in a genetically uniform strain. These mice are invaluable in research owing to their consistent genetic background, which minimizes variability in experimental studies. Inbred strains are used extensively in the study of genetics, immunology, and disease models, including as platforms for developing genetically engineered models and for pharmacological and toxicological studies. Outbred mice are genetically diverse populations that are kept deliberately heterozygous. This genetic variability mirrors the genetic diversity within human populations, making them particularly useful for toxicology, pharmacology, and safety assessment studies.

Application: Rising adoption of mice models to explore therapeutic efficacy and safety profiles before clinical trials

The applications of mice models in drug discovery and development are essential for the pharmaceutical industry. The physiological and genetic similarities between humans and mice make them invaluable for assessing the efficacy and safety of new pharmaceutical compounds. By utilizing mice models, researchers can elucidate the pharmacokinetic and pharmacodynamic properties of potential therapeutic agents, enabling the identification of promising drug candidates for further development. Moreover, these models help in understanding the mechanism of action, dose-response relationship, and potential toxicity of new drugs before entering human clinical trials, thereby minimizing the risk of failure at later development stages. Mice models are pivotal in the advancement of personalized medicine. Using genetically engineered mice and patient-derived xenografts (PDX), researchers can mimic human genetic conditions and diseases at a high level of accuracy. This enables the study of individual responses to therapeutics based on genetic makeup, leading to more precise and effective treatment strategies. Personalized mice models are instrumental in identifying biomarkers for disease diagnosis, predicting therapeutic outcomes, and evaluating targeted therapies. Besides their significant role in drug development and personalized medicine, mice models are extensively used in various biomedical research applications. These include studying genetics, understanding disease mechanisms, testing immunological responses, and evaluating the impact of environmental factors on health. Mice models have been crucial in advancing our knowledge of complex diseases such as cancer, cardiovascular diseases, diabetes, and neurological disorders. Their versatility and adaptability also make them suitable for regenerative medicine studies and aging research, contributing profoundly to expanding biomedical knowledge and exploring new therapeutic avenues.

Regional Insights

The mice model market is growing significantly in the Americas owing to continuous research activities by research organizations and pharmaceutical companies. Moreover, federal government support in terms of grants and investment for drug development and vaccine development has enhanced the scope of the mice model in the region. However, the rising genetic disease and neurological complications in European countries have increased the utilization of mouse models to understand age-related diseases. In addition, emerging clinical research institutes and favorable government initiatives drive market development in the EMEA region. The rising need for personalized medications, surging geriatric disease, increasing cases of immune disease, and growing prevalence of infectious disease boost the adoption of mice models across the Americas and Europe regions. On the other hand, the Asia-Pacific region witnesses significant growth prospects of the mice models market in the forecast period owing to growing research activities and government initiatives for clinical activities. APAC's increasing population and prevalence of chronic diseases underscore the need for extensive research, thereby propelling the adoption of mice models.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Mice Model Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Mice Model Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Mice Model Market, highlighting leading vendors and their innovative profiles. These include Applied StemCell, Inc., Aragen Life Sciences Ltd., Biocytogen Boston Corporation, Charles River Laboratories International, Inc., CompareNetworks, Inc., Creative Biolabs., Crown Bioscience by JSR Life Sciences, LLC, Cyagen US Inc. by PolyGene AG, Envigo by Inotiv, Inc., GenOway, Harbour BioMed, Horizon Discovery Ltd. by PerkinElmer, Inc., inGenious Targeting Laboratory, Inc., ITR Laboratories Canada, Janvier Labs, Marshall BioResources, MD Biosciences, Mirimus, Inc., Oncodesign, SA, Ozgene Pty Ltd., PhoenixBio Co., Ltd., Shanghai Model Organisms Center, Inc., Taconic Biosciences, Inc., The Jackson Laboratory, TransCure bioServices, Translational Drug Development, LLC, Transnetyx, Inc., Urosphere SAS, Vivo Bio Tech Ltd., and XenOPAT SL by Bellvitge Biomedical Research Institute.

Market Segmentation & Coverage

This research report categorizes the Mice Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Conditioned/Surgically Modified Mice
- Genetically Engineered Mice
- Hybrid/Congenic Mice
- Inbred Mice
- Outbred Mice

Technology
- CRISPR/CAS9
- Embryonic Stem Cell Injection
- Microinjection
- Nuclear Transfer

Therapeutic Area
- Cardiovascular Diseases
- Immunology
- Metabolic Diseases
- Neurology
- Oncology

Application
- Drug Discovery & Development
- Personalized Medicine
- Research Application

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Mice Model Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Mice Model Market?

3. What are the technology trends and regulatory frameworks in the Mice Model Market?

4. What is the market share of the leading vendors in the Mice Model Market?

5. Which modes and strategic moves are suitable for entering the Mice Model Market?

Product Code: MRR-4316E4E89369

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Escalating use of mice models for drug testing and research of immune disease
  - 5.1.1.2. Rising investments and grants coupled with surging pharmaceutical R&D activities
- 5.1.2. Restraints
  - 5.1.2.1. High costs associated with development of mice models
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging implementation of AI and ML in mice modeling
  - 5.1.3.2. Advent of CRISPR-Cas9 technology in mice modeling
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations and laws considering the ethical use of animals in research
5.2. Market Segmentation Analysis
- 5.2.1. Type: Growing significance of genetically engineered mice for evaluating gene therapy outcomes
- 5.2.2. Application: Rising adoption of mice models to explore therapeutic efficacy and safety profiles before clinical trials
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Mice Model Market, by Type

6.1. Introduction
6.2. Conditioned/Surgically Modified Mice
6.3. Genetically Engineered Mice
6.4. Hybrid/Congenic Mice
6.5. Inbred Mice
6.6. Outbred Mice

7. Mice Model Market, by Technology

7.1. Introduction
7.2. CRISPR/CAS9
7.3. Embryonic Stem Cell Injection
7.4. Microinjection
7.5. Nuclear Transfer

8. Mice Model Market, by Therapeutic Area

8.1. Introduction
8.2. Cardiovascular Diseases
8.3. Immunology
8.4. Metabolic Diseases
8.5. Neurology
8.6. Oncology

9. Mice Model Market, by Application

9.1. Introduction
9.2. Drug Discovery & Development
9.3. Personalized Medicine
9.4. Research Application

10. Americas Mice Model Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Mice Model Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Mice Model Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Biocytogen Officially Launches RenMice Series
- 13.3.2. Introducing NeoMab: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model
- 13.3.3. A Mouse That Roars: Chinese Scientists Create The First Mammal With Fully Reprogrammed Genes
- 13.3.4. UCLA Researchers Develop First Human Genomic Transgenic Mouse Model Of Huntington's Disease
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio